HK1206037A1 - 的人抗體及其使用方法 - Google Patents

的人抗體及其使用方法

Info

Publication number
HK1206037A1
HK1206037A1 HK15106491.4A HK15106491A HK1206037A1 HK 1206037 A1 HK1206037 A1 HK 1206037A1 HK 15106491 A HK15106491 A HK 15106491A HK 1206037 A1 HK1206037 A1 HK 1206037A1
Authority
HK
Hong Kong
Prior art keywords
gfr3
methods
human antibodies
antibodies
human
Prior art date
Application number
HK15106491.4A
Other languages
English (en)
Inventor
蘇珊‧
‧柯羅
黎恩‧麥克當諾
安德魯‧
‧墨菲
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49036666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1206037(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1206037A1 publication Critical patent/HK1206037A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
HK15106491.4A 2012-08-22 2015-07-07 的人抗體及其使用方法 HK1206037A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261692029P 2012-08-22 2012-08-22
PCT/US2013/055921 WO2014031712A1 (en) 2012-08-22 2013-08-21 HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
HK1206037A1 true HK1206037A1 (zh) 2015-12-31

Family

ID=49036666

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106491.4A HK1206037A1 (zh) 2012-08-22 2015-07-07 的人抗體及其使用方法

Country Status (34)

Country Link
US (5) US8968736B2 (zh)
EP (2) EP3450458B1 (zh)
JP (3) JP6392755B2 (zh)
KR (1) KR102158569B1 (zh)
CN (2) CN104768974B (zh)
AR (1) AR092188A1 (zh)
AU (1) AU2013305863B2 (zh)
CA (1) CA2879724C (zh)
CL (1) CL2015000420A1 (zh)
CY (1) CY1121097T1 (zh)
DK (1) DK2888280T3 (zh)
EA (2) EA202090031A3 (zh)
ES (1) ES2700160T3 (zh)
HK (1) HK1206037A1 (zh)
HR (1) HRP20190109T1 (zh)
HU (1) HUE042943T2 (zh)
IL (1) IL236738B (zh)
JO (1) JO3462B1 (zh)
LT (1) LT2888280T (zh)
MA (1) MA37945B1 (zh)
MX (1) MX363541B (zh)
MY (2) MY167920A (zh)
NZ (1) NZ704007A (zh)
PH (1) PH12015500114A1 (zh)
PL (1) PL2888280T3 (zh)
PT (1) PT2888280T (zh)
RS (1) RS58311B1 (zh)
SG (2) SG10201701376UA (zh)
SI (1) SI2888280T1 (zh)
TR (1) TR201816597T4 (zh)
TW (2) TWI631139B (zh)
UY (1) UY34988A (zh)
WO (1) WO2014031712A1 (zh)
ZA (1) ZA201500336B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
EP3838923B1 (en) 2012-08-24 2024-05-01 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
WO2016025884A1 (en) * 2014-08-14 2016-02-18 The Trustees Of The University Of Pennsylvania Glycosyl-phosphatidylinositol (gpi)-linked gdnf family alpha-receptor 4 (gfralpha4)-specific antibody and uses thereof
CA3013904C (en) * 2016-02-10 2023-12-12 Rutgers, The State University Of New Jersey Novel anti-lam and anti-pim6/lam monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections
US20170281756A1 (en) * 2016-02-25 2017-10-05 University Of Southern California Compositions and methods to selectively block pain induced by cold
WO2017147742A1 (en) * 2016-02-29 2017-09-08 Eli Lilly And Company Gfral receptor therapies
TWI815793B (zh) * 2016-03-31 2023-09-21 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
MX2018013885A (es) 2016-05-13 2019-08-16 Inst De Medicina Molecular Joaeo Lobo Antunes Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3).
SG11201811559WA (en) 2016-06-27 2019-01-30 Univ California Cancer treatment combinations
CN107827983B (zh) * 2017-11-06 2020-09-25 中国药科大学 一种靶向artn的单链抗体、制备方法及应用
EP3777889A4 (en) * 2018-03-26 2022-01-26 Shanghai Yile Biotechnology Co., Ltd. USE OF A PROBDNF REGULATOR IN B-LYMPHOCYTE ASSOCIATED DISEASES
WO2019210144A1 (en) * 2018-04-27 2019-10-31 Vanderbilt University Broadly neutralizing antibodies against hepatitis c virus
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
CN113645996B (zh) * 2019-02-01 2024-04-02 新石生物制药有限公司 抗claudin 18抗体及其使用方法
CA3134258A1 (en) * 2019-04-10 2020-10-15 Regeneron Pharmaceuticals, Inc. Human antibodies that bind ret and methods of use thereof
EP4041404A4 (en) 2019-09-30 2023-10-25 The Trustees of the University of Pennsylvania HUMANIZED ANTI-GDNF FAMILY ALPHA RECEPTOR 4 (GRF-ALPHA-4) ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS (CARS)
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
BR112023021256A2 (pt) 2021-04-20 2023-12-12 Regeneron Pharma Anticorpos humanos para artemina e métodos de uso dos mesmos
IL309027A (en) 2021-06-03 2024-02-01 Fundac?O D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud Neuro-messenger units that control ILC2 and obesity in brain fat cell circuit findings
WO2023144790A1 (en) * 2022-01-31 2023-08-03 Glaxosmithkline Intellectual Property (No.3) Limited Prevention and treatment of headaches

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138251B1 (en) 1996-04-22 2006-11-21 Amgen Inc. Polynucleotides encoding a neurotrophic factor receptor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US7026138B1 (en) * 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
NZ506748A (en) * 1998-03-23 2002-10-25 Genentech Inc Nucleic acids encoding a GFR alpha 3 polypeptide; host cell and vectors for production of the GRF alpha 3 protein and an assay for detecting GRFalpha 3 production
DK1640381T3 (da) * 1998-07-14 2014-07-14 Janssen Pharmaceutica Nv Neurotrofisk vækstfaktor
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
JP2008546716A (ja) * 2005-06-17 2008-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ＧＦＲα３抗体
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
KR101571027B1 (ko) * 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
US20090252729A1 (en) * 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
JP2010534469A (ja) 2007-07-25 2010-11-11 アストラゼネカ アクチボラグ Ｋｄｒ指向性標的化結合物質およびその使用
WO2009020964A2 (en) 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN103833855A (zh) 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
WO2012077649A1 (ja) * 2010-12-06 2012-06-14 大日本住友製薬株式会社 ヒトモノクローナル抗体
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها

Also Published As

Publication number Publication date
US20200040087A1 (en) 2020-02-06
WO2014031712A1 (en) 2014-02-27
TW201819415A (zh) 2018-06-01
SG10201701376UA (en) 2017-03-30
MA37945A1 (fr) 2016-02-29
PH12015500114B1 (en) 2015-03-16
HUE042943T2 (hu) 2019-07-29
PT2888280T (pt) 2019-01-21
JO3462B1 (ar) 2020-07-05
AU2013305863B2 (en) 2018-06-07
US20150110801A1 (en) 2015-04-23
ZA201500336B (en) 2019-12-18
CN104768974B (zh) 2018-08-14
CN109096398A (zh) 2018-12-28
HRP20190109T1 (hr) 2019-03-08
US9522185B2 (en) 2016-12-20
AU2013305863A1 (en) 2015-02-05
MY184241A (en) 2021-03-29
US8968736B2 (en) 2015-03-03
KR20150041664A (ko) 2015-04-16
US10077311B2 (en) 2018-09-18
TR201816597T4 (tr) 2018-11-21
MX2015002289A (es) 2016-06-07
JP2015532647A (ja) 2015-11-12
LT2888280T (lt) 2018-12-10
UY34988A (es) 2014-03-31
CN104768974A (zh) 2015-07-08
MA37945B1 (fr) 2017-05-31
US20170096488A1 (en) 2017-04-06
EP2888280A1 (en) 2015-07-01
KR102158569B1 (ko) 2020-09-22
MX363541B (es) 2019-03-27
BR112015003110A2 (pt) 2018-08-28
IL236738B (en) 2022-04-01
EP3450458A1 (en) 2019-03-06
PH12015500114A1 (en) 2015-03-16
CY1121097T1 (el) 2019-12-11
US20140056903A1 (en) 2014-02-27
MY167920A (en) 2018-09-27
TWI631139B (zh) 2018-08-01
EA034683B1 (ru) 2020-03-05
CA2879724A1 (en) 2014-02-27
JP2020031662A (ja) 2020-03-05
JP2018143252A (ja) 2018-09-20
CL2015000420A1 (es) 2015-05-22
ES2700160T3 (es) 2019-02-14
NZ704007A (en) 2018-08-31
EP2888280B1 (en) 2018-10-17
US20180340029A1 (en) 2018-11-29
EA201590402A1 (ru) 2015-09-30
TW201420603A (zh) 2014-06-01
US10947312B2 (en) 2021-03-16
JP6392755B2 (ja) 2018-09-19
PL2888280T3 (pl) 2019-04-30
JP6718482B2 (ja) 2020-07-08
DK2888280T3 (en) 2018-12-10
CA2879724C (en) 2023-03-14
EA202090031A2 (ru) 2020-04-30
IL236738A0 (en) 2015-02-26
EA202090031A3 (ru) 2020-07-31
EP3450458B1 (en) 2021-07-14
SI2888280T1 (sl) 2019-03-29
AR092188A1 (es) 2015-04-08
RS58311B1 (sr) 2019-03-29
SG11201500501VA (en) 2015-02-27
TWI613218B (zh) 2018-02-01

Similar Documents

Publication Publication Date Title
HRP20190109T1 (hr) Ljudska antitijela na gfr 3 i načini za njihovu primjenu
HK1202123A1 (zh) 針對 的人源抗體及其使用方法
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
SI2806892T1 (sl) Kombinirana terapevtska uporaba protiteles in endoglikozidaz
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
EP2938632A4 (en) ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE
HK1209432A1 (zh) 抗鋸齒蛋白抗體及使用方法
HK1206249A1 (zh) 人自分泌運動因子 的抗體及其使用方法